user

Results of a 12-month, multicenter, randomized trial of everolimus with reduced-exposure cyclosporine versus MMF and standard-exposure cyclosporine in De Novo cardiac transplant recipients

被引：0
|
作者：
Lebmkuhl, H. [1 ]
Livi, U. [2 ]
Arizon, J. [3 ]
Vigano, M. [4 ]
Magelli, C. [5 ]
Boissonnat, P. [6 ]
Gerosa, G. [7 ]
Musumeci, F. [8 ]
Gandjbakhch, I. [9 ]
Vanhaecke, J. [10 ]
Hexham, J. M. [11 ]
Mange, K. C. [11 ]
机构：
[1] Deutsch Herzzentrum Berlin, Berlin, Germany
[2] Osped S Maria Misericordia, Udine, Italy
[3] Hosp Univ Reina Sofia, Cordoba, Spain
[4] Univ Pavia, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy
[5] Az Osp Bologna, Policlin S Orsola, Bologna, Italy
[6] Hop Cardiol Lyon, Lyon, France
[7] Univ Padua, Azienda Osped Padova, Padua, Italy
[8] Osped S Camillo Forlanini Azienda Osped Circonval, Rome, Italy
[9] Hop La Pitie Salpetriere, Serv Chirurg Thorac & Cardiovasc, Paris, France
[10] Univ Hosp Gasthuisberg, Louvain, Belgium
[11] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2008年 / 27卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15
引用
收藏
页码：S65 / S65
页数：1
相关论文
共 50 条
  • [21] Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation
    Kovarik, JM
    Tedesco, H
    Pascual, J
    Civati, G
    Bizot, MN
    Geissler, J
    Schmidli, H
    THERAPEUTIC DRUG MONITORING, 2004, 26 (05) : 499 - 505
  • [22] 12-MONTH ATHENA STUDY: EVEROLIMUS VERSUS STANDARD REGIMEN IN DE NOVO RENAL TRANSPLANT RECIPIENTS
    Sommerer, C.
    Suwelack, B.
    Dragun, D.
    Hauser, I.
    Schenker, P.
    Baeumer, D.
    Nashan, B.
    Thaiss, F.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 450 - 450
  • [23] Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial
    Dantal, Jacques
    Berthoux, Francois
    Moal, Marie-Christine
    Rostaing, Lionel
    Legendre, Christophe
    Genin, Robert
    Toupance, Olivier
    Moulin, Bruno
    Merville, Pierre
    Rerolle, Jean-Philippe
    Bayle, Francois
    Westeel, Pierre Francois
    Glotz, Denis
    Kossari, Niloufar
    Lefrancois, Nicole
    Charpentier, Bernard
    Quere, Stephane
    Di Giambattista, Fabienne
    Cassuto, Elisabeth
    TRANSPLANT INTERNATIONAL, 2010, 23 (11) : 1084 - 1093
  • [24] Reduction of cyclosporine dose in maintenance cardiac transplant recipients after conversion from mmf/aza to everolimus: 12-month results from a pilot study
    Ross, Heather
    Burton, Jeffrey R.
    Pflugfelder, Peter
    Haddad, Haissam
    Cantarovich, Marcelo
    White, Michael
    Ignaszewski, Andrew
    Howlett, Jonathan
    Dorent, Richard
    Sips, Carole
    Vaillancourt, Marc
    TRANSPLANT INTERNATIONAL, 2007, 20 : 94 - 95
  • [25] Lower Incidence of Viral Infections with Everolimus Versus MMF in De Novo Heart Transplant Recipients: 12 Month Analysis of a Randomized Multicenter Study
    Ross, H.
    Kfoury, A. G.
    Van Bakel, A.
    Ewald, G.
    Burton, J.
    Andreassen, A.
    Segovia, J.
    Lopez, P.
    Cines, M.
    Dong, G.
    Potena, L.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2011, 30 (04): : S63 - S64
  • [26] Everolimus With Very Low-Exposure Cyclosporine A in De Novo Kidney Transplantation: A Multicenter, Randomized, Controlled Trial
    Salvadori, Maurizio
    Scolari, Maria Piera
    Bertoni, Elisabetta
    Citterio, Franco
    Rigotti, Paolo
    Cossu, Maria
    Dal Canton, Antonio
    Tisone, Giuseppe
    Albertazzi, Alberto
    Pisani, Francesco
    Gubbiotti, Giampiero
    Piredda, Gianbenedetto
    Busnach, Ghil
    Sparacino, Vito
    Goepel, Volker
    Messa, Piergiorgio
    Berloco, Pasquale
    Montanaro, Domenico
    Veroux, Pierfrancesco
    Federico, Stefano
    Bartezaghi, Marta
    Corbetta, Giuseppe
    Ponticelli, Claudio
    TRANSPLANTATION, 2009, 88 (10) : 1194 - 1202
  • [27] Everolimus Plus Reduced-Exposure Calcineurin Inhibitor Versus Mycophenolate Mofetil Plus Standard-Exposure Calcineurin Inhibitor: 2-Year Results in Living Donor Kidney Transplant Recipients
    Watarai, Y.
    Akutsu, N.
    Saito, K.
    Nakagawa, Y.
    Kamisawa, O.
    Kenmochi, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [28] Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab
    Budde, K.
    Bosmans, J.-L.
    Sennesael, J.
    Zeier, M.
    Pisarski, P.
    Schuetz, M.
    Fischer, W.
    Neumayer, H.-H.
    Glander, P.
    CLINICAL NEPHROLOGY, 2007, 67 (03) : 164 - 175
  • [29] Exposure-Response Analysis of Everolimus with Reduced Cyclosporine in Renal Transplant Recipients at 24 Months in a Randomized Trial.
    Shihab, F.
    Cibrik, D.
    Chan, L.
    Kim, Y. S.
    Carmellini, M.
    Walker, R.
    Zibari, G.
    Pattison, J.
    Cornu-Artis, C.
    Wang, Z.
    Jiang, H.
    Tedesco-Silva, H., Jr.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 298 - 299
  • [30] Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results
    Takahashi, Kota
    Uchida, Kazuharu
    Yoshimura, Norio
    Takahara, Shiro
    Teraoka, Satoshi
    Teshima, Rie
    Cornu-Artis, Catherine
    Kobayashi, Eiji
    TRANSPLANTATION RESEARCH, 2013, 2
12345